A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. - Wikidata - awgldk - TriplyDB

A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.

A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.

http://www.wikidata.org/entity/Q34608282

about

Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Progression of cutaneous melanoma: implications for treatment Regional therapies for in-transit disease Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion.Anesthesia management of patients undergoing hyperthermic isolated limb perfusion with melphalan for melanoma treatment: an analysis of 17 cases.Current treatment of locoregional recurrence of melanoma.Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution.Isolated limb infusion: Efficacy, toxicity and an evolution in the management of in-transit melanoma.A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.Development of regional chemotherapies: feasibility, safety and efficacy in clinical use and preclinical studies.A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ILI-alone in advanced extremity melanoma.Isolated limb infusion in a series of over 100 infusions: a single-center experience.Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma.The use of isolated limb infusion in limb threatening extremity sarcomas A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities.Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms Isolated limb infusion chemotherapy with or without hemofiltration for recurrent limb melanoma The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options.A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage IIIB or IIIC extremity melanoma Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma.Isolated limb infusion chemotherapy for melanoma: an overview of early experience at the Adelaide Melanoma Unit.Regional Therapy for Recurrent Metastatic Melanoma Confined to the Extremity: Hyperthermic Isolated Limb Perfusion vs. Isolated Limb Infusion.Quality of life after isolated limb infusion for in-transit melanoma of the extremity.Predicting disease progression after regional therapy for in-transit melanoma.A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion.Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?Optimizing regional infusion treatment strategies for melanoma of the extremities Pharmacotherapy of regional melanoma therapy.Isolated limb infusion with melphalan and actinomycin D in melanoma patients: factors predictive of acute regional toxicity.Regional treatment strategies for in-transit melanoma metastasis.Debulking surgery in advanced melanoma.Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review.Isolated limb infusion: technical aspects.Isolated limb perfusion with melphalan for melanoma.Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review.Isolated limb infusion as a model to test new agents to treat metastatic melanoma.Recent developments in the medical and surgical treatment of melanoma.Clinical Response and Regional Toxicity Following Isolated Limb Infusion Compared with Isolated Limb Perfusion for In-Transit Melanoma.Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma.

P2860

Q26770492-4E17488B-4E58-4F10-85CC-BA7399173514 Q27001734-6D69AAD6-83B0-4B11-BAED-F18D39690C5E Q28087553-90A177D0-07B1-4185-A907-4082C0243CDA Q34464096-451DDD81-B5C0-4AC0-A274-FECC18E70A0D Q34831510-4E77C342-210D-4A3D-87FB-66942F8EBD62 Q34888462-BEA54D34-3811-4AC8-A5D7-92B89F5A065B Q35127039-E9A5E10E-4147-4A2A-9428-374AB700654C Q35189712-9D1AC5D3-2231-474C-833A-120DC3045F12 Q35471445-586BC98B-2F38-4298-8889-4746873D5732 Q35646297-D6D09352-C542-4B49-8F6B-46C579F8D56F Q35731493-091E85B9-39A7-44C4-9270-8F8EC4BCDF55 Q35857551-3AFE0891-54F6-42F5-8754-85A2F794F8AE Q35857556-C6403975-3276-4DE5-AA38-D6F0D8384858 Q35861663-0E991983-8D74-480E-9C66-3628AB015B12 Q35871652-B9B18BDB-3813-4F03-825E-155AA06F99B5 Q35891767-22400525-7D31-4A86-8868-24860339F3B6 Q35891783-06C9BAC1-67AC-4EB1-90FC-E0A82CD6B162 Q35932694-8164E521-C2F2-4481-B226-FB08C5EB0F83 Q36102807-FEB00101-406F-4C5D-AD5C-0CB47046B624 Q36201336-75491778-3022-4F64-8DFC-430B02186397 Q36343055-E2BFFA50-3B26-4968-8CED-4D1049A83FC1 Q37120289-DAC6F0A7-EB83-43C8-8A43-0F3FAB4F8EBF Q37307175-F0A2239D-B0C2-4DD7-9948-138E4BAD842D Q37509676-30640BCD-C78F-412C-92FB-13708767E973 Q37509683-3B3F9971-9504-46FA-9526-FCD43D9D525D Q37509704-41D4197F-7381-48D5-B5F7-D90A470E7496 Q37513298-44DFD27B-0905-45DE-8817-4EE5A05029E7 Q37628698-D1C48620-FBE0-4958-809F-9E792E5B64EF Q37650312-871EDE00-AAC7-41AE-B47D-0D87E2519710 Q37770250-0834BDB8-AC9C-41C3-936F-E9E3128B69CF Q37812815-1D958BA6-6D90-4E2C-A3DD-37CAE5E27321 Q37952238-5E8171BE-B5E8-423C-AED7-A38529DCC593 Q38151728-7D2A88F5-F7B7-4ACB-9E3C-FB7CABEDDC84 Q38174452-D7F1C31C-B5CA-40E3-86C2-C43C1C3D5AC9 Q38178220-51CEDD1A-1E00-48E1-8C12-9399A5427C2D Q38187594-EC0568D6-235E-4819-82DD-284D16AD7F9F Q38187595-7FD549AB-4248-4096-8DDC-C15A7E34A8C3 Q38200004-B94BCFD0-3222-4D06-9E4C-44C581EC5115 Q38754840-D00617FB-9CB2-48F2-ACC6-2C220C75EABD Q38838678-FF99B076-D29A-4A38-AEAD-B55884DA26C9

P2860

A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US.

http://www.wikidata.org/entity/Q34608282

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

A multi-institutional experien ...... sponse and toxicity in the US.

@ast

A multi-institutional experien ...... sponse and toxicity in the US.

@en

A multi-institutional experien ...... sponse and toxicity in the US.

@nl

type

label

A multi-institutional experien ...... sponse and toxicity in the US.

@ast

A multi-institutional experien ...... sponse and toxicity in the US.

@en

A multi-institutional experien ...... sponse and toxicity in the US.

@nl

prefLabel

A multi-institutional experien ...... sponse and toxicity in the US.

@ast

A multi-institutional experien ...... sponse and toxicity in the US.

@en

A multi-institutional experien ...... sponse and toxicity in the US.

@nl

P1433

Q34608282-33398D17-7EFD-4006-AD9D-8B0FAF32D2D5

P1476

Q34608282-64A17B47-E07B-49A2-8049-E2E19809E9AE

P2093

Q34608282-13DF41AB-48FA-4578-8080-2D272F5161F2

Q34608282-3113FA77-47E9-4E4D-9007-818AA45CE0D4

Q34608282-38F479AB-B894-4156-9BAB-CC32B3630B58

Q34608282-40EFBAC7-0E15-4403-970E-4D3BCAAE8540

Q34608282-4ADD5629-1F27-4223-98C2-56B4A9495CB9

Q34608282-52E5AA12-C75E-40AF-9D83-553521C37240

Q34608282-61524027-697B-446E-9A29-1239D1F8FCF5

Q34608282-65D19A95-3079-4128-9964-4CBB0D3D2EBB

Q34608282-78DA9ADF-CF5E-456E-8467-33B2064E1316

Q34608282-7FA6AF56-079D-4C19-8E8D-5E091739ACBE

P304

Q34608282-DC395F99-AFC5-489A-A3F1-6CC760C24174

P31

Q34608282-8EA4234F-A32E-47CE-8FD6-7F90B9DFD9EA

P356

Q34608282-03D00458-69E1-4267-812C-F9425BF05C0C

P433

Q34608282-CCABBBD6-B9D3-4F5A-A19B-45FDB7E47901

P478

Q34608282-F6FE0A53-DB4F-4D48-B624-15A4079238A2

P50

Q34608282-AA25BC3C-E1D1-4BAB-BFE3-132FDBC5E79E

P577

Q34608282-04D1F705-54E0-42BF-ABAA-CDA445FA0D67

P5875

Q34608282-3EAC3557-9959-4C25-8F8F-712DE1B71965

P698

Q34608282-794D76CD-E3A5-40DE-8286-3A5A66B3C7C1

P356

J.JAMCOLLSURG.2008.12.019

P1433

Journal of the American College of Surgeons

P1476

A multi-institutional experien ...... sponse and toxicity in the US.

@en

P2093

Abigail Caudle

http://www.w3.org/2001/XMLSchema#string

Douglas S Tyler

http://www.w3.org/2001/XMLSchema#string

Hilliard Seigler

http://www.w3.org/2001/XMLSchema#string

James Padussis

http://www.w3.org/2001/XMLSchema#string

John M Kane

http://www.w3.org/2001/XMLSchema#string

Jonathan S Zager

http://www.w3.org/2001/XMLSchema#string

Keith A Delman

http://www.w3.org/2001/XMLSchema#string

Merrick I Ross

http://www.w3.org/2001/XMLSchema#string

Nicole S McMahon

http://www.w3.org/2001/XMLSchema#string

Paul J Mosca

http://www.w3.org/2001/XMLSchema#string

P304

706-15; discussion 715-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JAMCOLLSURG.2008.12.019

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

208

http://www.w3.org/2001/XMLSchema#string

P50

Georgia Beasley

P577

2009-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26248082

http://www.w3.org/2001/XMLSchema#string

P698

19476821

http://www.w3.org/2001/XMLSchema#string